Literature DB >> 16444762

Consumption costs and earnings during added years of life - a reply to Nyman.

Afschin Gandjour1.   

Abstract

Mesh：

Year:  2006        PMID： 16444762     DOI： 10.1002/hec.1065

Source DB:  PubMed          Journal:  Health Econ        ISSN： 1057-9230            Impact factor:   3.046


× No keyword cloud information.
  6 in total

Review 1.  Unrelated medical costs in life-years gained: should they be included in economic evaluations of healthcare interventions?

Authors:  David R Rappange; Pieter H M van Baal; N Job A van Exel; Talitha L Feenstra; Frans F H Rutten; Werner B F Brouwer
Journal:  Pharmacoeconomics       Date:  2008       Impact factor: 4.981

2.  From Good to Better: New Dutch Guidelines for Economic Evaluations in Healthcare.

Authors:  Matthijs Versteegh; Saskia Knies; Werner Brouwer
Journal:  Pharmacoeconomics       Date:  2016-11       Impact factor: 4.981

3.  Cost-effectiveness analysis of therapies for chronic kidney disease patients on dialysis: a case for excluding dialysis costs.

Authors:  Daniel T Grima; Lisa M Bernard; Elizabeth S Dunn; Philip A McFarlane; David C Mendelssohn
Journal:  Pharmacoeconomics       Date:  2012-11-01       Impact factor: 4.981

4.  Future costs in cost-effectiveness analysis: an empirical assessment.

Authors:  Marie Kruse; Jan Sørensen; Dorte Gyrd-Hansen
Journal:  Eur J Health Econ       Date:  2010-09-28

5.  Future Costs in Cost-Effectiveness Analyses: Past, Present, Future.

Authors:  Linda M de Vries; Pieter H M van Baal; Werner B F Brouwer
Journal:  Pharmacoeconomics       Date:  2019-02       Impact factor: 4.981

6.  Including Future Consumption and Production in Economic Evaluation of Interventions that Save Life-Years: Commentary.

Authors:  Erik Nord; Christoffer Lamøy
Journal:  Pharmacoecon Open       Date:  2018-12
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.